News stories about CytomX Therapeutics (NASDAQ:CTMX) have trended somewhat negative recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a news sentiment score of -0.12 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- CytomX Therapeutics, Inc. (NASDAQ:CTMX) Experiences Lighter than Average Trading Volume (highlightpress.com)
- Canaan Partners Closes Latest Venture Capital Fund, at $800M (finsmes.com)
- CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update (finance.yahoo.com)
- CytomX Therapeutics, Inc. (NASDAQ:CTMX) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
CytomX Therapeutics (NASDAQ CTMX) traded up 1.81% on Friday, reaching $14.08. The company had a trading volume of 85,558 shares. The stock’s 50 day moving average is $14.71 and its 200-day moving average is $14.36. The stock’s market capitalization is $517.43 million. CytomX Therapeutics has a 1-year low of $9.81 and a 1-year high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.32. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $2.10 million. On average, equities analysts predict that CytomX Therapeutics will post ($1.41) EPS for the current fiscal year.
A number of research analysts have recently weighed in on CTMX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a research report on Wednesday, April 26th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 29th. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. HC Wainwright reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research report on Monday, May 8th. Finally, ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $24.50.
In other news, CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $15.47, for a total value of $38,675.00. Following the transaction, the chief financial officer now owns 22,126 shares in the company, valued at $342,289.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Robert I. Tepper sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $16.00, for a total value of $240,000.00. Following the completion of the transaction, the insider now owns 44,777 shares in the company, valued at approximately $716,432. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,843 shares of company stock worth $572,703. Company insiders own 4.70% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.